Nivolumab and DA-EPOCH-R in Pediatric Primary Mediastinal (Thymic) Large B-cell Lymphoma
Nivolumab and DA-EPOCH-R in Pediatric Primary Mediastinal (Thymic) Large B-cell Lymphoma
Enrolling by invitation · NCT06871007 · Registry updated 2025-03-11Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Nivolumab and DA-EPOCH-R in Pediatric Primary Mediastinal (Thymic) Large B-cell Lymphoma | Children; Nivolumab; Primary Mediastinal (Thymic) Large B-cell Lymphoma | Enrolling by invitation | Phase 1 / Phase 2 | 2025-03-11 | NCT06871007 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| St. Petersburg State Pavlov Medical University | 16 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Dmitry Rogachev National Research Center | Moscow | Russia | 1 |
| Pavlov University, RM Gorbacheva Research Institute | Saint Petersburg | Russia | 2 |